Fulgent Genetics (FLGT) Free Cash Flow (2015 - 2026)

Fulgent Genetics has disclosed Free Cash Flow across 12 years of filings, most recently posting -$27.6 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 25.36% year-over-year to -$27.6 million; the TTM figure through Jun 2026 stood at -$103.8 million (down 73.12% YoY), while the FY2025 annual figure was -$124.2 million, down 545.09% from the prior year.
• Free Cash Flow came in at -$27.6 million for Q2 2026 at Fulgent Genetics, down from $1.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $183.1 million in Q1 2022 to a low of -$83.1 million in Q4 2025.
• Average Free Cash Flow over 5 years is $3.9 million, with a median of $2.6 million recorded in 2024.
• The largest YoY upside for Free Cash Flow was 132.29% in 2024 against a maximum downside of 759.13% in 2024.
• Over 5 years, Free Cash Flow stood at $28.5 million in 2022, then plunged by 58.48% to $11.8 million in 2023, then jumped by 79.59% to $21.2 million in 2024, then plunged by 491.35% to -$83.1 million in 2025, then soared by 66.78% to -$27.6 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$27.6 million in Q2 2026, $1.9 million in Q1 2026, and -$83.1 million in Q4 2025.